Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Martinez, Valérie ^a,b   Ta, Thi Dieu Ngan ^c   Mokhtari, Zahra ^d   Guiguet, Marguerite ^e   Miailhes, Patrick ^f   Valantin, Marc Antoine ^b,e   Charlotte, Fréderic ^b   Bertheau, Philippe ^g   Molina, Jean Michel ^g   Katlama, Christine ^b,e   Caumes, Eric ^b,e  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HANOI MEDICAL UNIVERSITY   (Viet Nam)

^d NATIONAL IRANIAN OIL COMPANY   (Iran)

^e INSERM   (France)

^f CROIX ROUSSE HOSPITAL   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

antiretroviral drugs; genotype 3; HCV; HIV; steatosis

Indexed keywords

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; FATTY LIVER; FEMALE; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER; MALE; METHODOLOGY; MIDDLE AGED; MIXED INFECTION; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; COINFECTION; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

EID: 84862169241     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-180     Document Type: Article

References (62)

1. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, Gonzalez A, Rockstroh J, Asensi V, et al. Clin Infect Dis 2004 38 1 128 133 Epub 2003 Dec 2008 10.1086/380130 14679458 (Pubitemid 38045883)
2. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, Chaisson RE, Moore RD, Sulkowski MS, Hepatology 2005 41 1 123 131 10.1002/hep.20541 15619237 (Pubitemid 40066390)
3. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U, Lancet 2003 362 9397 1708 1713 10.1016/S0140-6736(03)14844-1 14643119 (Pubitemid 37468321)
4. Hepatitis C virus infection. Lauer GM, Walker BD, N Engl J Med 2001 345 1 41 52 10.1056/NEJM200107053450107 11439948 (Pubitemid 32634271)
5. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ, Clin Infect Dis 2001 33 4 562 569 10.1086/321909 11462196 (Pubitemid 32709592)
6. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. Macias J, Castellano V, Merchante N, Palacios RB, Mira JA, Saez C, Garcia-Garcia JA, Lozano F, Gomez-Mateos JM, Pineda JA, AIDS 2004 18 5 767 774 10.1097/00002030-200403260- 00007 15075511 (Pubitemid 38535004)
7. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U, Lancet 2003 362 9397 1708 1713 10.1016/S0140-6736(03)14844-1 14643119 (Pubitemid 37468321)
8. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S, Gut 2003 52 7 1035 1040 10.1136/gut.52.7.1035 12801963 (Pubitemid 36765298)
9. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M, Clin Infect Dis 2001 33 10 1793 1795 10.1086/323009 11641832 (Pubitemid 33044553)
10. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Thein HH, Yi Q, Dore GJ, Krahn MD, AIDS 2008 22 15 1979 1991 10.1097/QAD.0b013e32830e6d51 18784461
11. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR, Clin Infect Dis 2001 32 3 492 497 10.1086/318501 11170959 (Pubitemid 32173638)
12. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL, AIDS 2005 19 6 585 592 10.1097/01.aids.0000163935. 99401.25 15802977 (Pubitemid 40543981)
13. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Pol S, Lebray P, Vallet-Pichard A, Clin Infect Dis 2004 38 Suppl 2 65 S72 14986277 (Pubitemid 38328167)
14. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Sterling RK, Contos MJ, Smith PG, Stravitz RT, Luketic VA, Fuchs M, Shiffman ML, Sanyal AJ, Hepatology 2008 47 4 1118 1127 10.1002/hep.22134 18366118 (Pubitemid 351547898)
15. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, Degott C, Pol S, AIDS 2006 20 4 525 531 10.1097/01.aids.0000210606.63138.f5 16470116 (Pubitemid 43731596)
16. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. Gaslightwala I, Bini EJ, J Hepatol 2006 44 6 1026 1032 10.1016/j.jhep.2006.02. 009 16618518
17. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ, J Infect Dis 2005 192 11 1943 1949 Epub 2005 Nov 1942 10.1086/497608 16267765 (Pubitemid 41681892)
18. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL, Hepatology 2005 42 2 310 316 10.1002/hep.20805 16025515 (Pubitemid 41061083)
19. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT, et al. Clin Infect Dis 2006 43 3 365 372 10.1086/505495 16804853 (Pubitemid 44078910)
20. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hepatites virales CO3 Aquitaine Cohort. Neau D, Winnock M, Castera L, Bail BL, Loko MA, Geraut L, Dupon M, Ragnaud JM, Lacoste D, Lafon ME, et al. J Acquir Immune Defic Syndr 2007 45 2 168 173 10.1097/QAI. 0b013e318042e1db 17527092 (Pubitemid 46869809)
21. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. Sanchez-Conde M, Berenguer J, Miralles P, Alvarez F, Carlos Lopez J, Cosin J, Pilar C, Ramirez M, Gutierrez I, Alvarez E, Clin Infect Dis 2006 43 5) 640 644 16886160 (Pubitemid 44267128)
22. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Castera L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock M, Dabis F, Neau D, Aliment Pharmacol Ther 2007 26 1112 1489 1498 17903235 (Pubitemid 350178805)
23. HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3. Borghi V, Puoti M, Mussini C, Bellelli S, Angeletti C, Sabbatini F, Prati F, Cossarizza A, Esposito R, Antivir Ther 2008 13 8 1057 1065 19195331
24. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL, Hepatology 2002 36 3 729 736 10.1053/jhep.2002.35064 12198667 (Pubitemid 34977185)
25. Review article: non-alcoholic fatty liver disease and hepatitis Crisk factors and clinical implications. Sanyal AJ, Aliment Pharmacol Ther 2005 22 Suppl 2 48 51 16225473 (Pubitemid 41564383)
26. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE, Hepatology 1999 29 4 1215 1219 10.1002/hep.510290401 10094967 (Pubitemid 29168757)
27. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA, J Hepatol 2004 40 1 147 154 10.1016/S0168-8278(03)00479-3 14672626 (Pubitemid 38064724)
28. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS, Am J Gastroenterol 2003 98 9 2064 2071 10.1111/j.1572-0241.2003.07640.x 14499789 (Pubitemid 37185807)
29. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ, J Infect Dis 2005 192 11 1943 1949 10.1086/497608 16267765 (Pubitemid 41681892)
30. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Brinkman K, Clin Infect Dis 2000 31 1 167 169 10.1086/313921 10913416 (Pubitemid 32268958)
31. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ, Curr Opin Lipidol 2004 15 1 59 67 10.1097/00041433-200402000-00011 15166810 (Pubitemid 39118019)
32. Hyperlactataemia syndromes associated with HIV therapy. Ogedegbe AE, Thomas DL, Diehl AM, Lancet Infect Dis 2003 3 6 329 337 10.1016/S1473-3099(03) 00654-6 12781504 (Pubitemid 36718011)
33. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR, Am J Gastroenterol 1999 94 9 2467 2474 10.1111/j.1572-0241.1999. 01377.x 10484010 (Pubitemid 29420675)
34. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group, Hepatology 1994 20 1 Pt 1 15 20 8020885
35. The fatty liver in AIDS. Tien PC, Grunfeld C, Semin Gastrointest Dis 2002 13 1 47 54 11944634 (Pubitemid 34262951)
36. Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection. Bauerle J, Miquel R, Laguno M, Mallolas J, Murillas J, Gatell JM, Walker UA, AIDS 2005 19 13 1441 1442 10.1097/01.aids.0000180782.70988.18 16103783 (Pubitemid 41800688)
37. Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection. Bauerle J, Miquel R, Laguno M, Mallolas J, Murillas J, Gatell JM, Walker UA, AIDS 2005 19 13 1441 1442 10.1097/01.aids.0000180782.70988.18 16103783 (Pubitemid 41800688)
38. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. Gaslightwala I, Bini EJ, J Hepatol 2006 44 6 1026 1032 10.1016/j.jhep.2006.02. 009 16618518
39. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, Degott C, Pol S, AIDS 2006 20 4 525 531 10.1097/01.aids.0000210606.63138.f5 16470116 (Pubitemid 43731596)
40. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Castera L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock M, Dabis F, Neau D, Aliment Pharmacol Ther 2007 26 1112 1489 1498 17903235 (Pubitemid 350178805)
41. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS, Gastroenterology 2011 140 3 809 817 10.1053/j.gastro.2010.11.052 21134375
42. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ, J Infect Dis 2005 192 11 1943 1949 Epub 2005 Nov 1942 10.1086/497608 16267765 (Pubitemid 41681892)
43. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL, Hepatology 2005 42 2 310 316 10.1002/hep.20805 16025515 (Pubitemid 41061083)
44. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hepatites virales CO3 Aquitaine Cohort. Neau D, Winnock M, Castera L, Bail BL, Loko MA, Geraut L, Dupon M, Ragnaud JM, Lacoste D, Lafon ME, et al. J Acquir Immune Defic Syndr 2007 45 2 168 173 10.1097/QAI. 0b013e318042e1db 17527092 (Pubitemid 46869809)
45. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL, AIDS 2005 19 6 585 592 10.1097/01.aids.0000163935. 99401.25 15802977 (Pubitemid 40543981)
46. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH, Hepatology 2004 40 6 1387 1395 10.1002/hep.20466 15565570 (Pubitemid 39657013)
47. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. Martin-Carbonero L, Soriano V, AIDS 2005 19 6 621 623 10.1097/01.aids.0000163939.08811.10 15802981 (Pubitemid 40543985)
48. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D, Gut 2004 53 3 420 424 10.1136/gut.2002. 009936 14960527 (Pubitemid 38241341)
49. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Kumar D, Farrell GC, Fung C, George J, Hepatology 2002 36 5 1266 1272 10.1053/jhep.2002.36370 12395339 (Pubitemid 35253445)
50. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 20062010. Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA, et al. BMC Infect Dis 2010 10 303 10.1186/1471-2334-10-303 20969743
51. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G, Hepatology 2001 33 6 1358 1364 10.1053/jhep.2001.24432 11391523 (Pubitemid 32496971)
52. Hepatitis C virus-induced hepatocellular steatosis. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM, Am J Gastroenterol 2005 100 3 711 715 10.1111/j.1572-0241.2005.40898.x 15743372 (Pubitemid 40487573)
53. Hepatitis C virus: the viral way to fatty liver. Clement S, Negro F, J Hepatol 2007 46 6 985 987 10.1016/j.jhep.2007.03.005 17445938 (Pubitemid 46669740)
54. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM, J Viral Hepat 2004 11 5 455 458 10.1111/j.1365-2893.2004.00528.x 15357652 (Pubitemid 39336228)
55. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG, J Hepatol 2004 40 3 484 490 10.1016/j.jhep.2003.11.004 15123364 (Pubitemid 38230851)
56. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, et al. J Hepatol 2000 33 1 106 115 10.1016/S0168-8278(00)80166-X 10905593 (Pubitemid 30418941)
57. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD, Am J Gastroenterol 1995 90 9 1433 1436 7661164
58. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD, AIDS 2004 18 17 2277 2284 10.1097/00002030-200411190- 00008 15577540 (Pubitemid 39620220)
59. Y B, Systemic overview of HAART- associated liver enzyme elevations in patients infected with HIV and co-infected with HCV. In: 13 th Conference on Retroviruses and Opportunistic Infections 2006 Denver, CO, US 2006
60. Steatohepatitis: a tale of two "hits"? Day CP, James OF, Gastroenterology 1998 114 4 842 845 10.1016/S0016-5085(98)70599-2 9547102 (Pubitemid 28160420)
61. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? Bauerle J, Laguno M, Mauss S, Mallolas J, Murillas J, Miquel R, Schmutz G, Setzer B, Gatell JM, Walker UA, HIV Med 2005 6 2 135 139 10.1111/j.1468-1293.2005.00276.x 15807720 (Pubitemid 40425978)
62. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL, Hepatology 2002 36 3 729 736 10.1053/jhep.2002.35064 12198667 (Pubitemid 34977185)